vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $9.5M, roughly 1.4× ECB Bancorp, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -34.7%, a 62.0% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 33.8%). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs -26.3%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
ECBK vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $13.8M |
| Net Profit | $2.6M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -18.5% |
| Net Margin | 27.3% | -34.7% |
| Revenue YoY | 33.8% | 73.8% |
| Net Profit YoY | 79.5% | -141.1% |
| EPS (diluted) | $0.32 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $13.8M | ||
| Q3 25 | $8.8M | $12.5M | ||
| Q2 25 | $8.0M | $9.7M | ||
| Q1 25 | $6.9M | $8.8M | ||
| Q4 24 | $7.1M | $7.9M | ||
| Q3 24 | $6.6M | $7.0M | ||
| Q2 24 | $6.3M | $7.3M | ||
| Q1 24 | $6.2M | $25.4M |
| Q4 25 | $2.6M | $-4.8M | ||
| Q3 25 | $2.4M | $-638.0K | ||
| Q2 25 | $1.4M | $-3.2M | ||
| Q1 25 | $1.3M | $-1.2M | ||
| Q4 24 | $1.4M | $-2.0M | ||
| Q3 24 | $1.1M | $-5.7M | ||
| Q2 24 | $791.0K | $-5.6M | ||
| Q1 24 | $621.0K | $12.8M |
| Q4 25 | 36.7% | -18.5% | ||
| Q3 25 | 37.0% | -1.5% | ||
| Q2 25 | 23.9% | -28.3% | ||
| Q1 25 | 24.9% | -9.2% | ||
| Q4 24 | 27.3% | -11.8% | ||
| Q3 24 | 23.3% | -74.6% | ||
| Q2 24 | 16.9% | -69.4% | ||
| Q1 24 | 13.4% | 54.2% |
| Q4 25 | 27.3% | -34.7% | ||
| Q3 25 | 27.7% | -5.1% | ||
| Q2 25 | 18.0% | -32.7% | ||
| Q1 25 | 18.7% | -13.3% | ||
| Q4 24 | 20.3% | -25.0% | ||
| Q3 24 | 17.2% | -82.2% | ||
| Q2 24 | 12.6% | -76.5% | ||
| Q1 24 | 10.0% | 50.6% |
| Q4 25 | $0.32 | $-0.17 | ||
| Q3 25 | $0.29 | $-0.02 | ||
| Q2 25 | $0.17 | $-0.11 | ||
| Q1 25 | $0.16 | $-0.04 | ||
| Q4 24 | $0.18 | $-0.02 | ||
| Q3 24 | $0.14 | $-0.21 | ||
| Q2 24 | $0.09 | $-0.20 | ||
| Q1 24 | $0.07 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $35.5M |
| Total Assets | $1.6B | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $36.8M | ||
| Q3 25 | $201.9M | $21.9M | ||
| Q2 25 | $191.0M | $18.7M | ||
| Q1 25 | $143.7M | $22.7M | ||
| Q4 24 | $309.4M | $26.6M | ||
| Q3 24 | $114.8M | $40.3M | ||
| Q2 24 | $108.7M | $43.1M | ||
| Q1 24 | $109.8M | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $171.9M | $35.5M | ||
| Q3 25 | $169.3M | $-4.5M | ||
| Q2 25 | $168.3M | $-7.5M | ||
| Q1 25 | $168.6M | $-5.9M | ||
| Q4 24 | $168.3M | $-5.9M | ||
| Q3 24 | $166.0M | $-5.2M | ||
| Q2 24 | $166.5M | $-1.4M | ||
| Q1 24 | $165.8M | $3.0M |
| Q4 25 | $1.6B | $70.6M | ||
| Q3 25 | $1.6B | $49.3M | ||
| Q2 25 | $1.5B | $44.9M | ||
| Q1 25 | $1.5B | $46.4M | ||
| Q4 24 | $1.4B | $44.9M | ||
| Q3 24 | $1.4B | $58.9M | ||
| Q2 24 | $1.3B | $63.2M | ||
| Q1 24 | $1.3B | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-6.0M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-6.0M | ||
| Q3 25 | $4.0M | $1.5M | ||
| Q2 25 | $1.9M | $-3.7M | ||
| Q1 25 | $-631.0K | $-4.3M | ||
| Q4 24 | $6.2M | $-1.5M | ||
| Q3 24 | $861.0K | $-2.2M | ||
| Q2 24 | $1.4M | $-8.4M | ||
| Q1 24 | $-429.0K | $39.0M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-649.0K | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -9.4% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
